Face Detection in Poor Quality Videos

Táto bakalárska práca sa venuje problematike detekcie tvárí v nekvalitných videozáznamoch, pričom sa konkrétne zameriava na prekryté tváre. Popisuje základné princípy algoritmov strojového učenia a ich métody, ktoré sú často využívané v oblasti počítačového videnia. Z nich sú bližšie priblížené konvolučné neurónové siete a ich state of the art modely zamerané detekciu tvárí. V praktickej časti boli vytvorené a natrénované modely na detekciu tvárí inšpirované známym state of the art modelom RetinaFace. Najlepšia varianta z nich dosauje na WIDER Face HARD testovacom sete 85,5% priemernú presnosť a na testovacom sete zameranom na prekryté tváre 90,9%. Súčasťou práce je aj program s grafickým uživateľským rozhraním, ktorý poskytuje nástroje na použitie vytrénovaných modelov na videu a obrázkoch.This bachelor thesis deals with face detection in low quality videos, while mainly focusing on occluded faces. It describes elementary priciples of machine learning algorithms and their methods, which are often used in the field of computer vision. Out of them are more closely described convolutional neural networks and their state of the art models focused on face detection. Out of those, convolutional neural networks and state of the art models for face detection are more closely described. For the practical part face detection models inspired by state of the art model RetinaFace were implemented and trained. The best performing model achieves 85.5% average precision on WIDER Face HARD testing dataset and 90.9% on dataset focused on occluded faces. Part of this thesis is also a program with graphical user interfaces which provides tools to use developed models on videos and pictures.

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Measurement of the very rare K+→π+ννˉK^+ \to \pi^+ \nu \bar\nu decay

The decay K+→π+νν¯ , with a very precisely predicted branching ratio of less than 10−10 , is among the best processes to reveal indirect effects of new physics. The NA62 experiment at CERN SPS is designed to study the K+→π+νν¯ decay and to measure its branching ratio using a decay-in-flight technique. NA62 took data in 2016, 2017 and 2018, reaching the sensitivity of the Standard Model for the K+→π+νν¯ decay by the analysis of the 2016 and 2017 data, and providing the most precise measurement of the branching ratio to date by the analysis of the 2018 data. This measurement is also used to set limits on BR(K+→π+X ), where X is a scalar or pseudo-scalar particle. The final result of the BR(K+→π+νν¯ ) measurement and its interpretation in terms of the K+→π+X decay from the analysis of the full 2016-2018 data set is presented, and future plans and prospects are reviewed

Kaon Physics in Europe

A review of selected recent results from experiments studying rare kaon decays in Europe is given. The results from the NA62 experiment at CERN are summarized in the first part of this report. The experiment produced a new preliminary upper limit on the $K^{ + } \to \pi ^{ + }\nu \bar{\nu }$ branching ratio of 1.85 × 10^−10 at 90% CL, based on the data recorded in 2016 and 2017. NA62 also performed searches for production of heavy neutral leptons (N) in $K^{ + } \to \ell ^{ + }N$ ($\ell = e,\mu$), and for lepton number violating processes $K^{ + } \to \pi ^{ - }\ell ^{ + }\ell ^{ + }$ ($\ell = e,\mu$). No significant signal was observed in these searches, and the world-leading upper limits have been set. In the second part of this review, we summarize the first observation and the branching ratio measurement of the $K^{ \pm } \to \pi ^{ \pm }\pi ^{0}e^{ + }e^{ - }$ decay by the NA48/2 experiment, a new preliminary measurement of the $K_{S} \to \pi ^{ \pm }\mu ^{ \mp }\nu$ branching ratio by the KLOE experiment, and a new upper limit on the $K_{S} \to \mu ^{ + }\mu ^{ - }$ branching ratio by the LHCb experiment

New limits on heavy neutrino from NA62

The NA62 experiment at CERN collected large samples of charged kaon decays in flight with a minimum bias trigger configuration in 2007 and in 2015 using a completely new detector setup. Upper limits on the rate of the charged kaon decay into a muon and a heavy neutral lepton (HNL) obtained from 2007 data and limits for the charged kaon decay into an electron and a HNL obtained from 2015 data, are reported in this proceedings

New measurement of the radiative decay Ke3γK e3\gamma at the NA62 experiment at CERN

The NA62 experiment at CERN reports new results from the study of the radiative kaon decay $K^+ \to \pi^0 e^+ \nu \gamma$ ($Ke3\gamma$), using a data sample recorded in 2017 and 2018. Preliminary results with the most precise measurement of the $Ke3\gamma$ branching ratio, and a T-asymmetry measurement in the $Ke3\gamma$ decay, are presented

Syntheses, spectroscopic study and X-ray crystallography of some new phosphoramidates and lanthanide(III) complexes of N-(4-nitrobenzoyl)-N′, N′′-bis(morpholino)phosphoric triamide

New phosphoramidates with the formula RC(O)N(H)P(O)X2, R = 2-NO2-C6H4, 3-NO2-C 6H4 and 4-NO2-C6H4, X = N(CH2CH3) (1)-(3), NC4H8 (4)-(6), and NC 4H8O (7)-(9) were synthesized and characterized by 1H, 13C, 31P NMR and IR spectroscopy, and elemental analysis. The reaction of (9) with hydrated lanthanide(III) nitrate leads to ten-or nine-coordinated complexes, (10)-(13). The crystal structure has been determined for (3), (5), (9), (10) and (13). In contrast to all of the previously reported similar phosphoramidate compounds, the-C(O)-N(H)-P(O) skeleton in the free ligand (9) shows a cisoid conformation, with the C=O and P=O double bonds adopting a nearly syn conformation. Quantum chemical calculations were applied for clarifying this exceptional conformational behavior. The monodentate neutral ligand (9) is coordinated to the metal ions via the phosphoryl O atom, adopting the usual anti conformation between the C=O and P=O groups. © 2010 International Union of Crystallography Printed in Singapore - all rights reserved.Fil: Gholivand, Khodayar. Tarbiat Modares University; IránFil: Mostaanzadeh, Hossein. Tarbiat Modares University; IránFil: Koval, Tomas. Academy of Sciences of the Czech Republic. Institute of Physics; República ChecaFil: Dusek, Michal. Academy of Sciences of the Czech Republic. Institute of Physics; República ChecaFil: Erben, Mauricio Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; ArgentinaFil: Stoeckli Evans, Helen. Universite de Neuchatel; SuizaFil: Della Vedova, Carlos Omar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Química Inorgánica "Dr. Pedro J. Aymonino". Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de Química Inorgánica "Dr. Pedro J. Aymonino"; Argentina. Comision de Investigaciones Cientificas de la Provincia de Buenos Aires. Unidad Plapimu Laseisic.; Argentin